NewsRoom Articles - Page 95 of 207

TuesdayAug 30, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product

CNS Pharmaceuticals is currently undertaking a potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine administered after first-line therapy for the treatment of recurrent glioblastoma multiforme (“GBM”) GBM is an aggressive form of cancer that occurs in the brain or spinal cord In the U.S., it affects between 12,000-15,000 new patients annually with a median survival rate of only 14.6 months from its diagnosis CNS’s drug development program is targeting the GBM drug market which is expected to expand at a CAGR of more than 4% between 2020 and 2030 On July 24, 2021, pre-clinical…

MondayAug 29, 2022 11:48 am

Study Looks into Why Deadly Brain Tumors Continue to Grow After Treatment

Gliomas are rare and fatal brain tumors that form when glial cells in the body grow uncontrollably. Glial cells usually support nerves in the body by helping an individual’s central nervous system function. These deadly tumors typically grow in the brain but may, in some cases, also grow in the spinal cord. New research has discovered that gliomas adapt to their surrounding brain environment in response to cancer treatment, developing interactions with nearby immune cells and neurons that prevent tumor cells from being identified easily by the body’s immune system. The study was conducted by an international team of experts,…

FridayAug 26, 2022 11:46 am

Study Explains How Threatening Cues Are Refined into Fear Signals

The fight-or-flight response is synonymous with most life forms. In moments of acute stress, your sympathetic nervous system will activate a sudden release of hormones that trigger a single response: fight or flight. Fear plays a major role in activating this response because it is usually activated in dire moments when a quick decision could be the difference between life and death. Scientists from the Salk Institute who were researching how the brain gathers threatening cues and distills them into fear signals have found a molecular pathway that plays a major role in creating the fear response. This pathway distills…

FridayAug 26, 2022 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector

Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain's connectivity patterns CYBN is leading the industry in developing proprietary psychedelic-based therapeutics The company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder The status of psilocybin is evolving as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. Cybin (NEO: CYBN) (NYSE American: CYBN) is on the leading edge of this transformation, as the clinical-stage biopharmaceutical company focuses on progressing psychedelics to therapeutics by offering a new standard of care for mental-health disorders…

ThursdayAug 25, 2022 11:34 am

Israeli Study identifies Bacterial Footprint in PTSD Sufferers

A new study has found that saliva samples can be used to accurately and rapidly diagnose individuals suffering from post-traumatic stress disorder, or PTSD. PTSD is a mental health condition that is triggered by an individual witnessing or experiencing a terrifying event. The study was carried out by scientists from the Tel Aviv University and the University of Haifa in Israel. For their research, the scientists obtained samples of saliva from some 200 Israeli soldiers and studied their medical, social and psychological conditions. The research, which was led by Professor Illana Gozes of the Sackler Faculty of Medicine, found that…

ThursdayAug 25, 2022 10:30 am

Phase I Trial Advance for Concussion Drug Leads Odyssey Health, Inc. (ODYY) to Prepare to Launch the Efficacy Analysis Stage for its Product

Brain concussion injuries have commanded a new level of respect in recent years as military personnel, athletes and care center administrations seek remedies rather than simply encouraging people to “shake off” a hard hit to the head Odyssey Health is advancing clinical trials for its novel PRV-002 drug / device solution for treating concussion patients The company reported completion of four cohorts of testing for safety in human subjects in August, and is preparing to launch Phase II testing that will evaluate the product’s efficacy PRV-002 is administered intranasally where it can be taken up across the blood-brain barrier by…

WednesdayAug 24, 2022 11:40 am

Study Finds Patients with Hodgkin’s Lymphoma Have Higher Risk of Developing Mental Illnesses

New research has found that Hodgkin’s lymphoma patients have a higher likelihood of suffering from substance-abuse and mental health disorders, in comparison to the general population. Hodgkin’s lymphoma works by attacking an individual’s immune system. The highly curable cancer is said to be prevalent in those aged between 15 and 39. This cancer type affects young individuals going through major transitions and events in their lives, such as starting their careers and attending college. Data from the National Cancer Institute shows that in the last five decades, death from Hodgkin’s lymphoma has dramatically reduced in comparison to any other cancer.…

TuesdayAug 23, 2022 11:35 am

Study Finds That Early Exposure to Antibiotics May Trigger Asthma, Permanent Allergies

A new study from Rutgers University has revealed that antibiotics can be a double-edged sword when used in early childhood. The study found that even though early exposure to antibiotics can be effective against bacterial infections in early childhood, they also kill off “good” bacteria in the digestive tract. Furthermore, the study found that early childhood exposure to antibiotics can also cause allergies and asthma later in life. The study, which published its findings in the “Mucosal Immunology” journal, adds to the growing body of research that indicates antibiotic exposure during the early childhood years is associated with the late…

MondayAug 22, 2022 12:01 pm

Report Details Most Prevalent Symptoms of Six Cardiovascular Illnesses

A scientific statement documenting the findings of a review conducted about the current scientific information available on the symptoms of different cardiovascular diseases has pointed out which symptoms are most common and how symptom presentation varies based on other factors, including age, sex and race, among others. One of the notable observations that the report makes is that it is important to move away from depending on only a physician’s assessment of symptom severity to relying more on self-reported symptom severity because the latter is a more reliable pointer of how serious the cardiovascular disease may be. Self-reported symptoms also…

MondayAug 22, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate

Odyssey Health is a medical company focused on developing unique, life-saving medical products that offer clinical advantages for unmet clinical needs Recently, the company reported positive results from Cohort I of its Multi-Day Ascending Dosing (“MAD”) portion of its Phase I clinical trial, coming weeks after the successful completion of Phase I Single Ascending Dosing (“SAD”) clinical trial The MAD arm thus far shows that the drug is safe and well tolerated Odyssey expects to report additional MAD results as they become available A few weeks after completing its Phase I Single Ascending Dosing (“SAD”) clinical trial, Odyssey Health (OTC:…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product

Study Looks into Why Deadly Brain Tumors Continue to Grow After Treatment

Study Explains How Threatening Cues Are Refined into Fear Signals

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector

Israeli Study identifies Bacterial Footprint in PTSD Sufferers

Phase I Trial Advance for Concussion Drug Leads Odyssey Health, Inc. (ODYY) to Prepare to Launch the Efficacy Analysis Stage for its Product

Study Finds Patients with Hodgkin’s Lymphoma Have Higher Risk of Developing Mental Illnesses

Study Finds That Early Exposure to Antibiotics May Trigger Asthma, Permanent Allergies

Report Details Most Prevalent Symptoms of Six Cardiovascular Illnesses

Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search